Market Cap | 35.85K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -3.22M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 15.00% |
Sales | 138.19k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
Dividend | N/A | Price/Book | EPS next 5Y | - | 52W High Chg | -50.00% | |
Recommedations | - | Quick Ratio | - | Shares Outstanding | 3.59K | 52W Low Chg | 100.00% |
Insider Own | - | ROA | - | Shares Float | - | Beta | 55.44 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00010 |
Gross Margin | 46.80% | Profit Margin | - | Avg. Volume | 6,508,195 | Target Price | - |
Oper. Margin | -411.87% | Earnings Date | - | Volume | 1,450,000 | Change | 0.00% |
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company is based in Scottsdale, Arizona.
Cantor Fitzgerald | Neutral | Feb 3, 21 |
Cantor Fitzgerald | Neutral | Jan 29, 21 |
Benchmark | Speculative Buy | Sep 9, 20 |
Cantor Fitzgerald | Neutral | Aug 13, 20 |
Cantor Fitzgerald | Neutral | May 18, 20 |
Benchmark | Speculative Buy | Dec 19, 19 |
Cantor Fitzgerald | Neutral | Nov 8, 19 |
Benchmark | Speculative Buy | Sep 10, 19 |